An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
复制标题
DOI：
10.1038/s41467-020-17317-y
复制
发表时间：
2020-07-06
影响因子：
16.6
通讯作者：
Koopmans, Marion
中科院分区：
文献类型：
--
作者：
GeurtsvanKessel, Corine H.;Okba, Nisreen M. A.;Koopmans, Marion
全球正进入COVID-19大流行的新时代，对可靠抗体检测的需求日益增加。为了支持在人群筛查或诊断中部署血清学的决策，我们对血清学COVID-19检测进行了详细比较。我们表明，在选定的检测中，在不同情况下以及与病毒中和抗体相关时，检测性能存在广泛的多样性。万泰ELISA检测针对SARS CoV-2受体结合结构域的总免疫球蛋白，具有检测疾病不同阶段和严重程度的功能抗体的最佳总体特征，包括可能设置指示保护性抗体存在的截止值。在决定部署用于特定应用的检测方法之前，需要对大量可用的血清学检测方法进行适当的检测方法验证。SARS-CoV-2正在引起全球大流行，其中血清学的实施可以支持不同情况下的决策。在这里，作者比较了八种市售检测方法与病毒中和的结果，并讨论了它们在SARS-CoV-2诊断和暴露评估中的应用。
The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications. SARS-CoV-2 is causing a global pandemic in which the implementation of serology can support decision making in different scenarios. Here, the authors compare the outcome of eight commercially available assays to virus neutralization and discuss their use in diagnostics and exposure assessment of SARS-CoV-2.